1. Abstract 1.1. Aims: This review aims to provide an overview of candidate biomarkers derived from MS-based proteomics representing inflammation or fibrosis in NAFLD and ALD.
1. Abstract Randomized controlled trials are the gold standard for eliminating bias in determining the efficacy and safety of medical products. However, the high costs, long duration, limited generalizability, and ethical or technical feasibility of RCTs have impelled investigators to look for real-world studies as alternatives.
1. Abstract Chronic hepatitis B virus (HBV) infection leads to a heavy disease burden globally, which is disproportionately high in Asia Pacific region. The currently available antiviral therapy can effectively suppress HBV replication but is not capable of eliminating the virus. Many new drugs aiming at HBV cure are under investigation in recent years, most …
1. Abstract For chronic hepatitis B (CHB) clinical trials, new challenges in the selection of the appropriate clinical endpoints were issued with the rapidly evolving concepts in designing, conducting and analyzing clinical trials.
1. Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) has become a significant health concern not only in the US but also worldwide due to the global obesity epidemic.
1. Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) has increasingly become a common cause of liver cirrhosis, hepatocellular carcinoma, and liver-related death. Currently, there are no therapeutic drugs that have proven efficacy and safety through randomized controlled clinical trial.
1. Abstract With the increasingly global epidemic of obese and metabolic syndrome, non-alcoholic steatohepatitis (NASH) has become a growing common cause of cirrhosis, hepatocellular carcinoma, and end-stage liver disease.
1. Abstract In recent years, the prevalence of liver diseases such as hepatitis B (or C) virus infection (HBV or HCV), non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have received much attention world-wide.
1. Abstract 1.1. Introduction: Plexiform Fibromyxoma (PF), also known as plexiform angiomyxoid myofibroblastic tumour (PAMT) is a rare mesenchymal myxoid tumour originating in different areas of the digestive system. Symptoms and signs are usually elusive: the most common are abdominal discomfort, dyspepsia, nausea and gastrointestinal bleeding with anemia and hematemesis.
1. Abstract Caroli Disease (CD) or caroli syndrome is a rare congenital liver disease characterized by non-obstructive cystic dilatations of the intra-hepatic and rarely extra-hepatic bile ducts.